BR9609423A - Peptideos derivados da dolastatina e seus sais composicão farmaceutica processo para tratar um tumor em um mamifero e processo para preparar peptidos derivados da dolastatina ou seus sais - Google Patents

Peptideos derivados da dolastatina e seus sais composicão farmaceutica processo para tratar um tumor em um mamifero e processo para preparar peptidos derivados da dolastatina ou seus sais

Info

Publication number
BR9609423A
BR9609423A BR9609423A BR9609423A BR9609423A BR 9609423 A BR9609423 A BR 9609423A BR 9609423 A BR9609423 A BR 9609423A BR 9609423 A BR9609423 A BR 9609423A BR 9609423 A BR9609423 A BR 9609423A
Authority
BR
Brazil
Prior art keywords
dolastatin
salts
derived
peptides
mammal
Prior art date
Application number
BR9609423A
Other languages
English (en)
Inventor
Andreas Haupt
Franz Emling
Cynthia A Romerdahl
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of BR9609423A publication Critical patent/BR9609423A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BR9609423A 1995-06-07 1996-06-03 Peptideos derivados da dolastatina e seus sais composicão farmaceutica processo para tratar um tumor em um mamifero e processo para preparar peptidos derivados da dolastatina ou seus sais BR9609423A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides
PCT/EP1996/002392 WO1996040751A1 (en) 1995-06-07 1996-06-03 Novel dolastatin derivatives, their preparation and use

Publications (1)

Publication Number Publication Date
BR9609423A true BR9609423A (pt) 1999-06-29

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9609423A BR9609423A (pt) 1995-06-07 1996-06-03 Peptideos derivados da dolastatina e seus sais composicão farmaceutica processo para tratar um tumor em um mamifero e processo para preparar peptidos derivados da dolastatina ou seus sais
BR9609424-9A BR9609424A (pt) 1995-06-07 1996-06-03 Novos peptìdeos, compostos, composição farmacêutica, processo para tratar um tumor em um mamìfero, e, processo para preparar os compostos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9609424-9A BR9609424A (pt) 1995-06-07 1996-06-03 Novos peptìdeos, compostos, composição farmacêutica, processo para tratar um tumor em um mamìfero, e, processo para preparar os compostos

Country Status (33)

Country Link
US (1) US5831002A (pt)
EP (2) EP0871656B1 (pt)
JP (2) JP4221062B2 (pt)
KR (2) KR100437985B1 (pt)
CN (2) CN1182154C (pt)
AR (2) AR003427A1 (pt)
AT (2) ATE224910T1 (pt)
AU (2) AU725170B2 (pt)
BG (2) BG102125A (pt)
BR (2) BR9609423A (pt)
CA (2) CA2219818C (pt)
CO (2) CO4700527A1 (pt)
CZ (2) CZ293682B6 (pt)
DE (2) DE69623992T2 (pt)
DK (2) DK0832104T3 (pt)
ES (2) ES2186783T3 (pt)
HR (2) HRP960257A2 (pt)
HU (2) HU228071B1 (pt)
IL (2) IL122215A (pt)
MX (2) MX9709147A (pt)
MY (2) MY119042A (pt)
NO (2) NO318384B1 (pt)
NZ (2) NZ310444A (pt)
PL (2) PL185762B1 (pt)
PT (2) PT871656E (pt)
RO (2) RO118953B1 (pt)
SI (2) SI0832104T1 (pt)
SK (1) SK282466B6 (pt)
TR (2) TR199701545T1 (pt)
TW (2) TW508357B (pt)
UA (2) UA46776C2 (pt)
WO (2) WO1996040751A1 (pt)
ZA (2) ZA964710B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) * 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6395897B1 (en) 1999-03-02 2002-05-28 Boehringer Ingelheim Pharmaceuticals, Inc. Nitrile compounds useful as reversible inhibitors of #9 cathepsin 5
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7018642B2 (en) 2001-04-27 2006-03-28 The Procter & Gamble Company Compounds, compositions, and methods for controlling biofilms
AU2002359792A1 (en) * 2001-12-18 2003-06-30 Proteologics, Inc. Methods and compositions for the inhibition of viral release
WO2003072754A2 (en) * 2002-02-27 2003-09-04 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
WO2006013552A2 (en) 2004-08-02 2006-02-09 Ramot At Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
EP1924245A2 (en) * 2005-08-19 2008-05-28 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
EP1973928A2 (en) * 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
US8163792B2 (en) 2006-05-16 2012-04-24 Pharmascience Inc. IAP BIR domain binding compounds
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Iap阻害剤
CN101674835B (zh) * 2007-04-12 2013-12-11 台湾神隆股份有限公司 制备加兰他敏的方法
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EA201391756A1 (ru) * 2011-05-27 2014-05-30 Амбркс, Инк. Композиции, содержащие, способы, включающие, и применение производных доластатина, связанных с неприродными аминокислотами
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
DK0934950T3 (da) * 1991-08-09 2002-07-29 Teikoku Hormone Mfg Co Ltd Tetrapeptidderivat
CZ292612B6 (cs) * 1992-05-20 2003-11-12 Abbott Gmbh & Co. Kg Peptid s protirakovinnou aktivitou, jeho použití a farmaceutický prostředek s obsahem takového peptidu
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters

Also Published As

Publication number Publication date
HUP9801910A3 (en) 1999-06-28
ATE224910T1 (de) 2002-10-15
IL122215A (en) 2001-08-26
DK0871656T3 (da) 2003-01-27
AU725164B2 (en) 2000-10-05
SK165397A3 (en) 1998-10-07
DE69623472T2 (de) 2003-08-21
NO975710D0 (no) 1997-12-05
NO975710L (no) 1998-02-02
MY124487A (en) 2006-06-30
US5831002A (en) 1998-11-03
PT871656E (pt) 2002-12-31
CA2219819A1 (en) 1996-12-19
HU228071B1 (hu) 2012-09-28
UA46775C2 (uk) 2002-06-17
CZ376397A3 (cs) 1998-06-17
PL185763B1 (pl) 2003-07-31
EP0871656B1 (en) 2002-09-25
ES2188759T3 (es) 2003-07-01
CN1182154C (zh) 2004-12-29
JPH11504652A (ja) 1999-04-27
CN1187198A (zh) 1998-07-08
RO118953B1 (ro) 2004-01-30
UA46776C2 (uk) 2002-06-17
DK0832104T3 (da) 2003-01-06
HU228073B1 (hu) 2012-09-28
KR19990022582A (ko) 1999-03-25
PL185762B1 (pl) 2003-07-31
PL323723A1 (en) 1998-04-14
TR199701545T1 (xx) 1998-04-21
DE69623992D1 (de) 2002-10-31
TR199701544T1 (xx) 1998-03-21
IL122216A0 (en) 1998-04-05
CA2219818C (en) 2008-05-20
NZ310443A (en) 1999-10-28
SI0871656T1 (en) 2003-08-31
ZA964710B (en) 1997-12-08
CN1187199A (zh) 1998-07-08
IL122216A (en) 2002-02-10
IL122215A0 (en) 1998-04-05
MX9709146A (es) 1998-03-31
BG102125A (en) 1998-09-30
DE69623472D1 (de) 2002-10-10
NO317670B1 (no) 2004-11-29
EP0832104B1 (en) 2002-09-04
CZ376597A3 (cs) 1998-06-17
WO1996040751A1 (en) 1996-12-19
WO1996040752A1 (en) 1996-12-19
ZA964711B (en) 1997-12-08
AR003136A1 (es) 1998-07-08
NO975711D0 (no) 1997-12-05
NO975711L (no) 1998-01-30
HUP9801817A3 (en) 1999-06-28
DE69623992T2 (de) 2003-05-22
TW508357B (en) 2002-11-01
AR003427A1 (es) 1998-08-05
NO318384B1 (no) 2005-03-14
HUP9801817A2 (hu) 1998-11-30
BR9609424A (pt) 2000-03-28
CO4700526A1 (es) 1998-12-29
NZ310444A (en) 1999-11-29
JP3957751B2 (ja) 2007-08-15
PL323726A1 (en) 1998-04-14
SI0832104T1 (en) 2003-08-31
AU725170B2 (en) 2000-10-05
CZ293682B6 (cs) 2004-07-14
KR100437986B1 (ko) 2004-09-18
MY119042A (en) 2005-03-31
PT832104E (pt) 2002-12-31
KR19990022583A (ko) 1999-03-25
HRP960257A2 (en) 1998-02-28
CN1182153C (zh) 2004-12-29
HRP960277A2 (en) 1997-10-31
CA2219818A1 (en) 1996-12-19
TW424096B (en) 2001-03-01
EP0832104A1 (en) 1998-04-01
ES2186783T3 (es) 2003-05-16
MX9709147A (es) 1998-03-31
EP0871656A1 (en) 1998-10-21
JPH11504653A (ja) 1999-04-27
KR100437985B1 (ko) 2004-09-18
AU6124296A (en) 1996-12-30
ATE223431T1 (de) 2002-09-15
JP4221062B2 (ja) 2009-02-12
HUP9801910A2 (hu) 1999-01-28
CZ293683B6 (cs) 2004-07-14
AU6124196A (en) 1996-12-30
CA2219819C (en) 2008-05-20
BG102152A (en) 1998-09-30
CO4700527A1 (es) 1998-12-29
RO119783B1 (ro) 2005-03-30
SK282466B6 (sk) 2002-02-05

Similar Documents

Publication Publication Date Title
BR9609423A (pt) Peptideos derivados da dolastatina e seus sais composicão farmaceutica processo para tratar um tumor em um mamifero e processo para preparar peptidos derivados da dolastatina ou seus sais
BR9610522A (pt) Composição para lavagem do corpo e processo para o tratamento da pele
BR9609152A (pt) Processo para tratamento de infecção por hiv em um individuo inibição da replicação do hiv e composição farmaceutica aceitavel util para o tratamento de infecção por hiv
BR9505996A (pt) Composição reticulada e processo para reicular polissacarideos contendo grupos ácidos ou seus sais
BR9612204A (pt) Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor
BR9408278A (pt) Anticorpo humanizado ou proteina de ligação do mesmo processo para a produção do mesmo composição farmacêutica e processos para o tratamento da doença de crohn e para o tratamento de MS
NO306342B1 (no) Syntetiske eksitatoriske aminosyrer, farmasöytisk formulering inneholdende slike aminosyrer samt mellomprodukt
BR9407264A (pt) Composição aquosa e método para tratar lentes de contato
BR9612135A (pt) Taxóides processo para sua preparação e composiç o farmacêutica
DE69526516D1 (de) Vorrichtung zur verabreichung von peptidwirkstoffen in aerosolform
DE69621779D1 (de) Faser zur verminderung von polarisationseffekten in verstärkern
BR9611198A (pt) Composto processo de preparação do mesmo e composição farmacêutica
PT797431E (pt) Formulacoes de peptidios e proteinas em aerossol
NO954612D0 (no) Metoder og preparater for å behandle ooforektomiserte kvinner
BR9404114A (pt) Composição farmacêutica e seu processo de preparação
BR9201017A (pt) Composicao de amaciamento de tecido e processo para sua preparacao
BR9100046A (pt) Derivados de azaoxindole,composicao farmaceutica e processo para o tratamento de mamiferos
BR9105287A (pt) Composicao e processo para o tratamento do cabelo
BR9407265A (pt) Composto composições farmacêuticas e métodos para tratamento de câncer em um mamifero
BR9600494A (pt) Composição cosmética não lavável e processo de tratamento cosmético não lavável de materiais queratínicos
BR9402961A (pt) Forma de dosagem farmacêutica seca por congelamento e processo para preparação da mesma
BR9506020A (pt) Composição aquosa e processo de preparaçao da mesma
BR9504090A (pt) Composição farmacêutica transdermicamente ativante processo para sua preparação e método de tratar câncer
FI965008A0 (fi) Koostumukset ja menetelmät kasvainten hoitamiseksi
DE69624214D1 (de) Hormonale medikamente und deren verwendung zur behebung von östrogenmangelerscheinungen

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 37, INDEFIRO O PRESENTE PEDIDO, TENDO POR BASE O ARTIGO 8O COMBINADO COM O ARTIGO 13 DA LPI 9279 DE 14/05/96.

B12B Appeal against refusal [chapter 12.2 patent gazette]